OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. The company's product candidates and preclinical programs include navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets Delta-like ligand 4 and vascular endothelial growth factor, which has completed a single-agent Phase Ia clinical trial in patients with advanced solid tumors, as well as in two Phase Ib clinical trials for patients with platinum-resistant ovarian cancer and metastatic colorectal cancer; anti-TIGIT (OMP-313M32), a T-cell immunoreceptor with immunoglobulin and ITIM domain, which is in Phase Ia clinical trial for patients with advanced or metastatic solid tumors; GITRL-Fc (OMP-336B11), a glucocorticoid-induced tumor necrosis factor receptor -related protein and its ligand, which is in Phase Ia clinical trial for patients with advanced or metastatic solid tumors; and rosmantuzumab (anti-RSPO3, OMP-131R10), a monoclonal antibody targeting the RSPO-LGR CSC pathway. It has strategic alliances with Celgene Corporation for discovery, development, and commercialization of novel small molecule therapeutics; and Bayer Pharma AG for discovery, development, and commercialization of anti- cancer stem cell biologic and small molecule therapeutics targeting the Wnt signaling pathway. OncoMed Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Redwood City, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OMED
CUSIPN/A
Phone650-995-8200
Debt
Debt-to-Equity RatioN/A
Current Ratio2.59
Quick Ratio2.59
Price-To-Earnings
Trailing P/E Ratio-2.47
Forward P/E Ratio-3.10
P/E GrowthN/A
Sales & Book Value
Annual Sales$38.15 million
Price / Sales2.59
Cash FlowN/A
Price / CashN/A
Book Value($1.28) per share
Price / Book-2.01
Profitability
EPS (Most Recent Fiscal Year)($1.04)
Net Income$-39,060,000.00
Net Margins-55.36%
Return on EquityN/A
Return on Assets-18.94%
Miscellaneous
Employees56
Outstanding Shares38,430,000
Oncomed Pharmaceuticals (NASDAQ:OMED) Frequently Asked Questions
What is Oncomed Pharmaceuticals' stock symbol?
Oncomed Pharmaceuticals trades on the NASDAQ under the ticker symbol "OMED."
How were Oncomed Pharmaceuticals' earnings last quarter?
Oncomed Pharmaceuticals Inc (NASDAQ:OMED) announced its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.07. The biopharmaceutical company had revenue of $7.85 million for the quarter, compared to analysts' expectations of $7.27 million. View Oncomed Pharmaceuticals' Earnings History.
When is Oncomed Pharmaceuticals' next earnings date?
What price target have analysts set for OMED?
5 equities research analysts have issued twelve-month price targets for Oncomed Pharmaceuticals' stock. Their forecasts range from $3.00 to $6.00. On average, they expect Oncomed Pharmaceuticals' stock price to reach $4.60 in the next twelve months. View Analyst Ratings for Oncomed Pharmaceuticals.
Are investors shorting Oncomed Pharmaceuticals?
Oncomed Pharmaceuticals saw a decline in short interest in the month of May. As of May 15th, there was short interest totalling 386,177 shares, a decline of 25.3% from the April 30th total of 516,962 shares. Based on an average daily trading volume, of 105,777 shares, the days-to-cover ratio is currently 3.7 days. Currently, 1.5% of the company's shares are sold short.
Who are some of Oncomed Pharmaceuticals' key competitors?
Some companies that are related to Oncomed Pharmaceuticals include American Brivision (Holding) (ABVC), Savara (SVRA), Albireo Pharma (ALBO), Tyme Technologies (TYME), Unum Therapeutics (UMRX), Corvus Pharmaceuticals (CRVS), Verastem (VSTM), Catalyst Pharmaceuticals (CPRX), Evelo Biosciences (EVLO), ProMetic Life Sciences (PFSCF), Aquinox Pharmaceuticals (AQXP), DURECT (DRRX), Arbutus Biopharma (ABUS), MediciNova (MNOV) and Paratek Pharmaceuticals (PRTK).
Who are Oncomed Pharmaceuticals' key executives?
Oncomed Pharmaceuticals' management team includes the folowing people:
- Mr. Perry A. Karsen, Exec. Chairman (Age 63)
- Dr. John A. Lewicki, Pres, CEO & Director (Age 66)
- Ms. Yvonne Li, VP of Fin. & Admin. and Controller (Age 58)
- Dr. Austin Gurney, Chief Scientific Officer & Sr. VP (Age 54)
- Dr. Alicia J. Hager, Sr. VP & Gen. Counsel (Age 48)
Has Oncomed Pharmaceuticals been receiving favorable news coverage?
News coverage about OMED stock has been trending somewhat positive recently, Accern reports. Accern identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Oncomed Pharmaceuticals earned a news impact score of 0.10 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 45.85 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
Who are Oncomed Pharmaceuticals' major shareholders?
Oncomed Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BVF Inc. IL (11.07%), Millennium Management LLC (0.61%), Spark Investment Management LLC (0.30%), Birchview Capital LP (0.26%), Sofinnova Ventures Inc (0.17%) and DRW Securities LLC (0.14%). Company insiders that own Oncomed Pharmaceuticals stock include Alicia J Hager, Jack W Lasersohn, John A Lewicki, Jonathan D Root, Paul J Hastings, Perry A Karsen, Sunil Patel, Timothy Hoey and Yvonne Li. View Institutional Ownership Trends for Oncomed Pharmaceuticals.
Which institutional investors are selling Oncomed Pharmaceuticals stock?
OMED stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and BVF Inc. IL. Company insiders that have sold Oncomed Pharmaceuticals company stock in the last year include Alicia J Hager, John A Lewicki, Paul J Hastings and Yvonne Li. View Insider Buying and Selling for Oncomed Pharmaceuticals.
Which institutional investors are buying Oncomed Pharmaceuticals stock?
OMED stock was bought by a variety of institutional investors in the last quarter, including Birchview Capital LP, Sofinnova Ventures Inc, Spark Investment Management LLC and DRW Securities LLC. Company insiders that have bought Oncomed Pharmaceuticals stock in the last two years include Jack W Lasersohn and Perry A Karsen. View Insider Buying and Selling for Oncomed Pharmaceuticals.
How do I buy shares of Oncomed Pharmaceuticals?
Shares of OMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Oncomed Pharmaceuticals' stock price today?
One share of OMED stock can currently be purchased for approximately $2.57.
How big of a company is Oncomed Pharmaceuticals?
Oncomed Pharmaceuticals has a market capitalization of $101.84 million and generates $38.15 million in revenue each year. The biopharmaceutical company earns $-39,060,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis. Oncomed Pharmaceuticals employs 56 workers across the globe.
How can I contact Oncomed Pharmaceuticals?
Oncomed Pharmaceuticals' mailing address is 800 Chesapeake Drive, Redwood City CA, 94063. The biopharmaceutical company can be reached via phone at 650-995-8200 or via email at [email protected]
MarketBeat Community Rating for Oncomed Pharmaceuticals (OMED)
MarketBeat's community ratings are surveys of what our community members think about Oncomed Pharmaceuticals and other stocks. Vote "Outperform" if you believe OMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
